Patient Selection Criteria for Low-Dose Ketamine Therapy

Introduction: The Importance of Appropriate Patient Selection

Appropriate patient selection for low-dose ketamine therapy is fundamental to achieving favorable clinical outcomes while minimizing adverse events and resource misallocation. Patient selection criteria for ketamine therapy must balance the robust efficacy data against the drug's unique safety profile, access requirements, and cost considerations to identify individuals most likely to derive meaningful benefit. As ketamine transitions from a research intervention to a mainstream clinical tool, the development of evidence-based selection frameworks becomes essential for standardizing clinical practice and ensuring equitable access (Sanacora et al., 2017).

The selection process encompasses multiple domains: diagnostic indication, severity and treatment resistance thresholds, medical and psychiatric contraindications, substance abuse risk assessment, psychosocial factors affecting treatment adherence, and practical considerations including patient preferences and treatment accessibility. Each domain contributes to an integrated clinical judgment that determines whether ketamine therapy is appropriate, and if so, what treatment format (IV, intranasal, oral) and clinical setting best match the individual patient's needs and risk profile.

Diagnostic Indications

Treatment-Resistant Depression

The strongest evidence base supports ketamine use in treatment-resistant depression (TRD), defined as failure to respond adequately to at least two antidepressant trials of adequate dose and duration. This indication is supported by multiple randomized controlled trials, systematic reviews, and the FDA's approval of intranasal esketamine specifically for TRD (Daly et al., 2018). The selection of TRD patients for ketamine should confirm:

• Diagnosis verification: Structured diagnostic assessment confirming major depressive disorder (ruling out bipolar depression, substance-induced mood disorder, medical causes of depression)
• Treatment adequacy: Documentation of prior antidepressant trials meeting adequacy criteria -- therapeutic dose maintained for minimum 4-8 weeks with adherence verification. The Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) provides a standardized framework for documenting treatment resistance level (Fava, 2003).
• Current severity: Moderate-to-severe depression severity, typically defined as MADRS greater than or equal to 20, PHQ-9 greater than or equal to 15, or HDRS-17 greater than or equal to 17. Mild depression may not justify the risks and costs of ketamine therapy when less intensive alternatives remain available.

Acute Suicidal Ideation

The rapid anti-suicidal effects of ketamine position it as a potential intervention for acute suicidal crises, supported by evidence demonstrating clinically meaningful reduction in suicidal ideation within hours of administration (Wilkinson et al., 2018). Patient selection for this indication involves:

• Severity assessment: Active suicidal ideation with intent or plan, as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) or equivalent
• Acuity: Acute presentation requiring rapid intervention, as opposed to chronic passive suicidal ideation
• Safety setting: Access to appropriate monitoring infrastructure (emergency department, inpatient unit, or crisis stabilization center with medical monitoring capability)

Chronic Pain Indications

Selection criteria for ketamine in chronic pain -- particularly neuropathic pain and central sensitization syndromes -- emphasize:

• Documented central sensitization: Evidence from quantitative sensory testing (temporal summation, impaired conditioned pain modulation) or clinical features (allodynia, widespread pain amplification) suggesting NMDA receptor-dependent pain mechanisms
• Treatment resistance: Inadequate response to first-line (gabapentinoids, duloxetine) and second-line (tricyclic antidepressants, topical agents) neuropathic pain treatments
• Functional impairment: Pain severity sufficient to produce meaningful functional disability warranting the risks and costs of ketamine intervention

Medical Contraindications

Absolute Contraindications

Conditions that represent absolute contraindications to ketamine administration:

• Uncontrolled hypertension: Systolic BP consistently greater than 180 mmHg or diastolic greater than 110 mmHg, given ketamine's sympathomimetic cardiovascular effects
• Active aneurysmal disease: Aortic or intracranial aneurysm, where acute blood pressure elevation poses risk of rupture
• Active psychotic symptoms: Hallucinations, delusions, or formal thought disorder not attributable to the depressive episode, given ketamine's psychotomimetic properties
• Known allergy/hypersensitivity to ketamine: Documented allergic reaction to ketamine or its formulation components
• Elevated intracranial pressure: Conditions associated with raised ICP (though the historical concern has been partially mitigated by contemporary evidence)
• Pregnancy (relative contraindication; see severity-based framework)

Relative Contraindications

Conditions requiring careful risk-benefit assessment and potentially enhanced monitoring:

• Controlled hypertension: Ketamine can be administered with enhanced hemodynamic monitoring and prophylactic blood pressure management
• Stable cardiovascular disease: Cardiology consultation and enhanced monitoring recommended
• History of psychotic disorder: Increased risk of transient psychotomimetic effects; monitor closely and ensure psychosis is in stable remission
• Active substance use disorder: Elevated abuse potential risk; supervised administration only with enhanced substance use monitoring
• Hepatic impairment: Altered ketamine metabolism may increase exposure; lower doses and enhanced hepatic monitoring recommended
• Urological disorders: Pre-existing lower urinary tract symptoms may be exacerbated; urological surveillance recommended

Psychiatric Screening Considerations

Bipolar Disorder Screening

Given the risk of treatment-emergent affective switch, all depression patients being evaluated for ketamine should be screened for bipolar spectrum disorders using validated instruments such as the Mood Disorder Questionnaire (MDQ) or Hypomania Checklist-32 (HCL-32). Patients with identified bipolar disorder should receive ketamine only in the context of concurrent mood stabilizer therapy (Diazgranados et al., 2010).

Psychotic Symptom Assessment

A thorough assessment for current or historical psychotic symptoms is essential. Active psychotic symptoms represent a contraindication, while a remote history of psychotic features during severe depressive episodes may represent a relative contraindication requiring careful risk-benefit analysis. The Brief Psychiatric Rating Scale (BPRS) positive symptom subscale provides a standardized assessment tool.

Personality Disorder Considerations

Patients with borderline personality disorder (BPD) present complex selection considerations. The impulsivity, emotional dysregulation, and interpersonal sensitivity characteristic of BPD may complicate the treatment relationship and increase the risk of both adverse psychological responses to ketamine and problematic medication-seeking behavior. However, some evidence suggests that BPD patients with comorbid depression may benefit from ketamine, and categorical exclusion based on personality diagnosis alone may not be warranted (Nair et al., 2020).

Psychosocial and Practical Selection Factors

Treatment Adherence Capacity

Ketamine therapy requires sustained engagement with a clinical program involving regular appointments, monitoring protocols, and post-treatment activity restrictions (no driving for 24 hours). Patients must demonstrate the capacity and willingness to adhere to these requirements. Factors affecting adherence capacity include transportation access, social support, work schedule flexibility, and cognitive/organizational ability.

Financial Accessibility

The cost of ketamine therapy -- ranging from approximately $400-800 per IV infusion session to $590-885 per esketamine (Spravato) session -- represents a significant financial barrier. Patient selection should include assessment of insurance coverage, out-of-pocket capacity, and the sustainability of financial commitment for the anticipated treatment duration. Initiating ketamine therapy that a patient cannot afford to complete risks treatment discontinuation at a suboptimal time point.

Support System

The requirement for a responsible companion for post-treatment transportation and the potential for psychological processing needs following ketamine sessions make social support an important selection consideration. Patients with strong support systems may be better positioned to engage safely with ketamine therapy, while isolated patients may require additional clinical scaffolding.

Biomarker-Guided Selection: Emerging Approaches

Inflammatory Biomarkers

Emerging evidence suggests that baseline inflammatory status -- measured by CRP, IL-6, or other peripheral markers -- may predict ketamine response, with elevated inflammation associated with greater antidepressant efficacy (Kiraly et al., 2017). If validated, CRP-based stratification could identify a depression subtype preferentially responsive to ketamine, enabling more precise patient selection.

Neuroimaging Predictors

Baseline default mode network connectivity, prefrontal cortex metabolism, and anterior cingulate cortex function have shown preliminary promise as neuroimaging predictors of ketamine response (Abdallah et al., 2017). While not yet clinically implementable, these biomarkers represent the frontier of precision selection that could transform ketamine prescribing from empirical trial to neurobiologically guided intervention.

Genetic Predictors

Pharmacogenomic markers including BDNF Val66Met polymorphism, GRIN2B variants, and CYP2B6 metabolizer status have been investigated as ketamine response predictors. Laje and colleagues (2012) reported that BDNF Val66Met genotype predicted antidepressant response to ketamine, published in Biological Psychiatry. These findings remain preliminary and have not been consistently replicated but foreshadow a future in which genetic testing may inform selection decisions.

A Clinical Decision-Making Framework

Step 1: Diagnostic Confirmation

Verify primary diagnosis using structured clinical assessment. Confirm treatment resistance through documented treatment history review.

Step 2: Contraindication Screen

Systematically assess for absolute and relative contraindications. Obtain specialist consultation as needed (cardiology, hepatology, addiction medicine).

Step 3: Risk-Benefit Assessment

Weigh the expected benefit (based on indication, severity, and available predictors) against the identified risks (based on contraindications, comorbidities, and abuse potential). Document the clinical reasoning.

Step 4: Practical Feasibility

Assess treatment adherence capacity, financial sustainability, support system, and preferences regarding treatment format and setting.

Step 5: Shared Decision-Making

Engage the patient in an informed consent discussion that includes a realistic presentation of expected benefits, risks, and alternatives, and document the shared decision.

Conclusion

Patient selection for low-dose ketamine therapy requires a systematic, multi-domain assessment that integrates diagnostic indication, severity thresholds, medical and psychiatric contraindications, abuse potential risk, psychosocial factors, and practical feasibility. The strongest evidence supports selection of patients with treatment-resistant depression who have failed at least two adequate antidepressant trials and who lack absolute contraindications. Emerging biomarker-based approaches -- incorporating inflammatory, neuroimaging, and genetic predictors -- hold promise for enhancing selection precision. A structured clinical decision-making framework that incorporates shared decision-making and thorough documentation provides the foundation for appropriate, equitable, and safe ketamine prescribing.

References

• PubMed: A Consensus Statement on the Use of Ketamine in Treatment of Mood Disorders — APA task force consensus on patient selection, safety monitoring, and clinical use of ketamine for mood disorders
• NIMH: Depression Overview — National Institute of Mental Health clinical information on depressive disorders and treatment-resistant depression
• MedlinePlus: Ketamine Injection Drug Information — National Library of Medicine medication information including contraindications and prescribing precautions
• FDA MedWatch: Safety Information and Adverse Event Reporting — FDA safety reporting system for monitoring ketamine-related adverse events and contraindication screening